Key result
Desipramine therapy triggered neuroleptic malignant syndrome in a patient without neuroleptic exposure, suggesting the syndrome may be caused by a norepinephrine-dopamine imbalance.
This case suggests that neuroleptic malignant syndrome may be caused by a central imbalance between norepinephrine and dopamine, rather than dopamine depletion alone.
No takes yet. Share an insight, caveat, or question.
Alerts to possible NMS with desipramine; hypothesis-generating for norepinephrine-dopamine imbalance mechanism.
Baca et al. (1990) studied this question. Desipramine therapy triggered neuroleptic malignant syndrome in a patient without neuroleptic exposure, suggesting the syndrome may be caused by a norepinephrine-dopamine imbalance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: